925 related articles for article (PubMed ID: 32204691)
1. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
4. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
[TBL] [Abstract][Full Text] [Related]
5. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
[TBL] [Abstract][Full Text] [Related]
6. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
[TBL] [Abstract][Full Text] [Related]
7. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.
Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS
Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
9. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
10. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
11. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.
El-Husseini A; Hannan S; Awad A; Jennings S; Cornea V; Sawaya BP
Am J Kidney Dis; 2015 Jan; 65(1):127-30. PubMed ID: 25446020
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
Kim MJ; Lee H; Kim YH; Jin SY; Kim HJ; Oh D; Jeon JS
BMC Nephrol; 2021 Mar; 22(1):86. PubMed ID: 33691638
[TBL] [Abstract][Full Text] [Related]
14. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation.
Java A
Adv Chronic Kidney Dis; 2020 Mar; 27(2):128-137. PubMed ID: 32553245
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Wijnsma KL; Duineveld C; Wetzels JFM; van de Kar NCAJ
Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
[TBL] [Abstract][Full Text] [Related]
16. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation.
Kawaguchi K; Kawanishi K; Sato M; Itabashi M; Fujii A; Kanetsuna Y; Huchinoue S; Ohashi R; Koike J; Honda K; Nagashima Y; Nitta K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():61-5. PubMed ID: 26031589
[TBL] [Abstract][Full Text] [Related]
17. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
Avila Bernabeu AI; Cavero Escribano T; Cao Vilarino M
Nephron; 2020; 144(11):537-549. PubMed ID: 32950988
[TBL] [Abstract][Full Text] [Related]
18. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome.
Ono M; Ohashi N; Namikawa A; Katahashi N; Ishigaki S; Tsuji N; Isobe S; Iwakura T; Sakao Y; Tsuji T; Kato A; Fujigaki Y; Shimizu A; Yasuda H
Intern Med; 2018 Jun; 57(11):1617-1623. PubMed ID: 29434134
[TBL] [Abstract][Full Text] [Related]
19. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
Kant S; Bhalla A; Alasfar S; Alachkar N
BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
[TBL] [Abstract][Full Text] [Related]
20. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
Levi C; Frémeaux-Bacchi V; Zuber J; Rabant M; Devriese M; Snanoudj R; Scemla A; Amrouche L; Mejean A; Legendre C; Sberro-Soussan R
Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
